Open-label Extension Study of Brazikumab in Ulcerative Colitis - Expedition

Study identifier:D5272C00002

ClinicalTrials.gov identifier:NCT04277546

EudraCT identifier:2021-001644-10

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)

Medical condition

ulcerative colitis

Phase

Phase 2

Healthy volunteers

No

Study drug

Brazikumab Maintenance Dose, Brazikumab Induction Dose

Sex

All

Actual Enrollment

57

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 03 Mar 2020
Primary Completion Date: 10 Oct 2023
Study Completion Date: 10 Oct 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria